Positive new data for Ceplene in acute myeloid leukemia

6 July 2017

Positive new clinical trial results on the use of Ceplene (histamine dihydrochloride) for relapse prevention in patients with acute myeloid leukemia (AML) have been published in the Leukemia, a leading hematology journal.

Ceplene is under development by Cytovia, the oncology subsidiary of US biotech Immune Pharmaceuticals (Nasdaq: IMNP). Immune regained rights to Ceplene from a unit of Mylan (Nasdaq: MYL) in January of this year.

Investigators from the Universities of Gothenburg, Sweden and Rome, Italy reported that functional NK cells are clinically relevant anti-leukemic effector cells in AML patients who received treatment with Ceplene/interleukin (IL)-2.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK